Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Mokliatchouk

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Human Heredity|November 30, 2000
Association tests for traits with variable age at onsetO Mokliatchouk, D Blacker, D Rabinowitz
British Journal of Cancer|June 2, 2011
Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapyC R Garrett, L L Siu, A El-Khoueiry, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2010
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumorsD J Jonker, L S Rosen, M B Sawyer, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Human Heredity|November 30, 2000
Association tests for traits with variable age at onsetO Mokliatchouk, D Blacker, D Rabinowitz
British Journal of Cancer|June 2, 2011
Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapyC R Garrett, L L Siu, A El-Khoueiry, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2010
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumorsD J Jonker, L S Rosen, M B Sawyer, et al.
Pageof 1